4Xue YL, Qiu ZL, Song HJ, et al. Value of lalI SPECT/CT for the evaluation of differentiated thyroid cancer: A systematic re- view of the literature. Eur J Nucl Med Mol Imaging, 2013, 40 (5) :768-778.
5Wakabayashi H, Nakajima K, Fukuoka M, et al. Double-phase (131)I whole body scan and 1311 SPECT-CT images in patientswith differentiated thyroid cancer: Their effectiveness for accurate identification. Ann Nucl Med, 2011,25(9):609-615.
6Rosdrio PW, De Faria S, Bicalho L, et ah Uhrasonographic dif- ferentiation between metastatic and benign lymph nodes in pa- tients with papillary thyroid carcinoma. J Ultrasound Med, 2005, 24(10) : 1385-1389.
7Kim DW, Choo H J, Lee YJ, et ah Sonographic features of cervi cal lymph nodes after thyroidectomy for papillary thyroid carcino- ma. J Ultrasound Med, 2013,32(7) :1173-1180.
8Gritzmann N, Hollerweger A, Macheiner P, et ah Sonography of soft tissue masses of the neck. J Clin Ultrasound, 2002, 30(6) : 356-373.
9Kloos RT, Mazzaferri EL. A single recombinant human thyrotro- pin stimulated serum thyroglobulin measurement predicts differ- entiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab, 2005,90:5047- 5057.
10Rajkovaca Z, Kovacevi P, Staneti M, et al. Assessment of re- combinant human thyrotropin application in following-up pa- tients with well-differentiated thyroid carcinoma. Vojnosanit Pregl, 2012,69(11) : 941-946.
